Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fepradinol is a small molecule aralkylamine with analgesic, antipyretic, and anti-inflammatory properties. It has been used for the treatment of pain and inflammation associated with conditions such as arthritis and musculoskeletal disorders. Fepradinol acts primarily as a beta‑adrenergic receptor antagonist (beta-blocker), which leads to decreased heart rate and reduced cardiac workload. Its anti-inflammatory activity does not appear to be related to inhibition of prostaglandin biosynthesis—a mechanism that distinguishes it from traditional NSAIDs. Preclinical studies have shown that it can inhibit both early and late phases of inflammatory responses more effectively than indomethacin in some models[2][4][6]. Clinical trials have explored its use in allergic contact dermatitis as well.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fepradinol.